Medtronic, a global leader in healthcare technology, will share new data for the Prevail™ Drug-Coated Balloon, Evolut™ PRO and PRO+, and Symplicity Spyral™ renal denervation (RDN) system at the upcoming 37th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The conference will showcase key data presentations and advancements across its Coronary, Structural Heart and Renal Denervation businesses in the Medtronic Cardiovascular Portfolio.
 

New evidence demonstrating the real-world usage of Prevail™ coronary paclitaxel drug-coated balloon (DCB) in complex populations including diabetic patients

Real-World Usage of the Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

Monday, Oct. 27, 9 a.m. Station 6 | Halls B-C | Exhibition Level | Moscone South | Moscone Center
Presenter: Prof. David Erlinge

New real-world data from Swedish Coronary Angiography and Angioplasty Registry (SCAAR) on the Prevail™ DCB¹, presented at TCT 2025, will highlight outcomes of Prevail™ paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (Prevail DCB) in patients with long lesions, multi-vessel disease and hybrid percutaneous coronary intervention (PCI). Prevail DCB is the only DCB with a CE Mark indication for multivessel disease.

CAUTION: Prevail is an investigational device in the US. Limited by Federal (US) law to investigational use. Not approved by FDA and not for sale in the US. Prevail DCB received CE mark in 2020, Prevail expanded indications are approved in the EU and UK only.

Real-World Usage of the Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

Monday, Oct. 27, 10 a.m. Room: Station 6 | Halls B-C | Exhibition Level | Moscone South | Moscone Center
Presenter: Prof. David Erlinge

New real-world data from Swedish Coronary Angiography and Angioplasty Registry (SCAAR) on the Prevail™ DCB, presented at TCT 2025, will highlight the safety and effectiveness of Prevail™ paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (Prevail DCB) in diabetic patients. Prevail DCB is the only DCB with a CE Mark indication for diabetic patients.

CAUTION: Prevail is an investigational device in the US. Limited by Federal (US) law to investigational use. Not approved by FDA and not for sale in the US. Prevail DCB received CE mark in 2020, Prevail expanded indications are approved in the EU and U.K. only.
 

Structural Heart and Aortic key data milestones at TCT:

Final Global Results from the Optimize PRO Study

Structural Scientific Abstracts/Session, Saturday, October 25 at 9:30 am PT. Room: Station 1 | Hall D
Presenter: Dr. Steven Yakubov

The final global results from the Optimize PRO Trial will demonstrate significant improvements in procedural outcomes for transcatheter aortic valve replacement (TAVR). Conducted across 50 global centers with 653 patients, the study evaluated the impact of optimized care pathways and advanced procedural techniques.
 

Medtronic advances Renal Denervation, showcasing durability and real-world experience

Durable Safety and Efficacy of Renal Denervation using the Symplicity Spyral Catheter in Patients Taking Antihypertensive Drugs: Final, 3-Year Results from the SPYRAL HTN-ON MED Randomized Study

Featured Clinical Research: October 26, 2:14 pm. Endovascular Spotlight Theater Hall F Presenter: D. Kandzari

This featured clinical research will report on the three years of the SPYRAL HTN-ON MED trial, which will look at blood pressure reductions in 24-hour ambulatory and office systolic blood pressure (SBP) compared with sham control in hypertensive patients.

 

First Report of the SPYRAL AFFIRM Study: Reduced Home and Office Blood Pressure Following Radiofrequency Renal Denervation in a Large U.S. Cohort of High Cardiovascular Risk Patients

Featured Clinical Research: October 27, 3:00 pm. Endovascular Spotlight Theater Hall F Presenter: F. Mahfoud

Professor Mahfoud’s presentation will add to the breadth of real-world data for Symplicity Spyral as a guideline-recommended treatment for uncontrolled high blood pressure. The SPYRAL AFFIRM study collected additional safety and efficacy data following RDN in high-cardiovascular-risk patient subgroups, predominantly from the US.

 

Same day discharge with the Symplicity Renal Denervation system: Outcomes from the real world Global Symplicity Registry DEFINE

Oral abstract: Monday, October 27 2:00 p.m. Endovascular Spotlight Theater Halls B-C Presenter: F. Mahfoud

This presentation will highlight the safety and effectiveness of same-day discharges following the Symplicity Blood Pressure procedure.

 

About Medtronic 
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow us on LinkedIn. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results. 

Contacts:
Krystin Hayward Leong
Public Relations
+1-508-261-6512

Ryan Weispfenning
Investor Relations
+1-763-505-4626